Member Info for noix

spawny
In the interview when talking about additional gas customers AK mentioned FIPL by name and that it should be up and running in H1. He then stopped abruptly and Malcy laughed because I believe he was about to let the cat out of the bag.
The cat in question I believe relates to this, which was released in the 22nd December rns and which I've mentoned before.
"In addition. a new gas sales agreement is being finalised with a significant new industrial gas sales customer, a subsidiary of a well-respected international company, based on the signed term sheet which was announced in June 2020."
I stand to be corrected but believe this to be in addition to the FIPL contract and one would hope is imminent. Perhaps they like signing contracts at the end of January :)

I believe it was a fair point but for me it was highly relevant that AK referenced the fact that the 2021 guidance excludes new contracts and as I've posted a bit earlier, there's one already nearing completion.
I like understating rather than the opposite and not coming up to expectations.

Yes as advised on 22nd December, they have this up their sleeve which when finalised will add to the 2021 guidance.
"In addition. a new gas sales agreement is being finalised with a significant new industrial gas sales customer, a subsidiary of a well-respected international company, based on the signed term sheet which was announced in June 2020."

Funnily enough I've just had a look into the CPX site where an investor Tony_P has just posted a comment on green energy and the effects that this will have on the super capacitor market. I will resist going into ramp mode but what he and you both post is sobering information and all the time China, India and even Germany et al continue to pollute the Earth and maintain a massive advantage in energy costs. Hence it pays to diversify.

Yes. it's very much the start of the journey and folk would be well advised to re-visit (or visit for the first time) the Audited Results in the 3rd November rns and to scroll down to the "business review" just after the Chairman's statement.
I'm sure with the potential and progress outlined in that review, we will be gettng plenty of updates moving forward.
https://www.investegate.co.uk/cap-xx-limited--cpx-/rns/replacement--audited-results/202011031249321197E/

How strange. When I originally posted it, my 10:17 was about 6 posts further down the bus, so apologies to those 6 posters for any misunderstanding.

Apparently every cloud has one and I suppose it means this is one more board I no longer need to moniter. Hopefully only in the short term.

If you folk want a detailed view of the above case then I suggest a 5 minute read of the excellent Mattjos posts over on advfn is well worth it.

xedos
On the face of it, the options appear to be priced in US dollars so an exercise price of £2.10 or CA$3.61.
In terms of Friday's price action I had a look at the historical GGP share price in the period that they entered the GDXJ. It fell quite sharply, then plateaued before rising over a 10 day period. That's not to say that PUR will do the same but it's always useful to have comparisons.

They don't actually have to invest in LOAC to invest in 4D Pharma, they can do it directly on the AIM.
At present this would be the sensible way of buying into 4D because with LOAC closing at $10.80 Friday evening (£8.13) and 7.5315 of the new "Consideration shares" being issued for every LOAC share, that's £1.08p against 4D's closing price of 96.6p last evening.

I see the above formality has been duly passed:
https://apnews.com/press-release/pr-newswire/business-corporate-news-ownership-changes-sec-filings-mergers-and-acquisitions-a206a0b0025c45d243d6ab822619b509

mishdosh
Thanks, I wasn't aware that one had to register, even after the event.
Just had a listen and will now collect my thoughts.

Is any one aware where the webcast can be viewed. I was unable to watch it on the day and was of the understanding that it was going to be posted on the 4D website.
TIA

Nice work if you can get it Matt.
In a nutshell, unless Longevity have got some assets I'm not ware of ( I havn't pored over their balance sheet but I doubt they would have been kept quiet ) then their share holders get 19.7 million 4D "consideration shares" in return for the listing and the $14.6 million, less $1.86 million, less costs. By my workings, that's a net 45.5p a share.

Just a little addition to that last post, I believe the Company could have made the mechanics much clearer had they published the net cash figure due to be received. I'm estimating 5% costs, which could be more or less.
Also if anyone believes my workings are wrong, particularly on the $28.29 vs $26.1 million, then please don't be shy :)

Matt2521
I believe the confusion arises because the money is just a part of the deal, arguably the larger attraction is the Nasdaq listing.
One confusing aspect of the original rns is that they say this:
" The Longevity Shareholders are expected to own approximately 13.1 per cent. of the issued share capital of 4D (based on the current issued share capital of 4D and Longevity) immediately following the Merger. Based on a price of £1.10 per 4D Ordinary Share, the 4D Ordinary Shares underlying the 4D ADSs to be issued in exchange for each Longevity Share in the Merger represent an aggregate value of approximately US$26.1 million."
The figure of $26.1 million is incorrect and by my reckoning should be $28.29 million, the market capital of LOAC when the deal was announced - 19,783,287 x £1.10 multiplied by $1.30.
In reality the share capital of LOAC is transferred to 4D for $14.6 million, less a $1.86 million liability and costs of say 5%, in exchange for the issue of the 19.78 million shares and of course the Nasdaq listing.
There's also the question of the Longevity warrants but that's for another time.

Matt 521
I've always stated that the best way to view this "merger" is that it's a placing at a premium (£1.10) to the closing price when the deal was announced of around 93p.
Longevity shareholders acquire 13.1% of the enlarged share capital of the Company (150,000,000 shares approx.) for the $14.6 million. I calculate that after liabilities ($1.86 million) and costs it's around £9 million. The shareholders get 7.5315 new shares for every Longevity share held and one 4D ADS for every 8 shares held. The big attraction is the Nasdaq listing, still planned for mid January. It would appear that in its articles, Longevity had a clause stating that it had to complete a deal as a SPAC by 30th November 2020. That's why they are holding the special meeting around the 20th November to authorise the extension to May 2021, which is obviously comfortably beyond the completion date envisaged of January 2021.
This was all flagged up in the original rns of 22nd October:

"Longevity intends to hold a shareholder meeting on or around 20 November 2020 in order to extend its Business Combination Deadline to 29 May 2021, thereby allowing sufficient time for all of the Conditions to be satisfied and for the Transaction to complete. 4D has received an irrevocable undertaking from Whale to vote in favour of the resolutions to effect the Transaction to be proposed at the general meeting of Longevity Shareholders in respect of holdings totalling, in aggregate, 1,250,000 Longevity Shares, representing 48 per cent. of Longevity 's outstanding shares of common stock.

The Transaction is currently expected to become effective in early 2021, subject to the approval of 4D Shareholders, Longevity Shareholders and the SEC review process."

Leisurely, your post of Monday night.
It was a poorly constructed rns with the actual conversion rate of 7.5315 4D new ordinary shares for every Longevity share hidden at the bottom in "Definitions".
And then they get one 4D ADS for every 8 consideration shares (the new issue of 19.783 million) held.

Don't worry Splodge. There are plenty with two left feet on here :)

I'd never encourage any one to put money into a share. That can only be your decision. What I do try to do is present the facts as I see them and peer groups of 4D Pharma have had long enough to pore over those results and I don't hear anyone disputing either the safety or efficacy as presented.
Good luck with whatever you decide but remember we are only at the start of the journey and there will be plenty of other opportunities to come on board or increase holdings at a later date.
Q takeover Monday morning :)